Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Enrolling ACRIA Trials

Fall 2002


Integrase Inhibitor

This trial will study the pharmacokinetics, safety and antiviral effect of S-1360, one of a new class of experimental anti-HIV medications that inhibit the integrase enzyme.

This is a ten-day study for people with HIV who have not taken antiretrovirals. People 18 years and older, with a viral load between 400 and 50,000 copies and a CD4 count over 50 may be eligible for the study. They must not have taken any protease inhibitors, nor been on any NRTIs for more than 2 weeks, nor have taken more than one dose of any NNRTI.

People in the study will be compensated up to $1,050 while they take part in the study to cover time lost from work, transportation costs, etc. For more information call Dr. Yuriy Akulov at 212-924-3934, ext. 124.

Advertisement

Ampligen and HAART: Protocol AMP 719

This trial will study the effects and safety of adding Ampligen to HAART and see if it helps to lower viral load.

Adults with a CD4 count over 300, and a viral load between 500 and 30,000 may be eligible for this study. The first 10 people in the trial will receive infusions of Ampligen twice a week, and take HAART. Later groups will either receive infusions at entry or receive them 6 months later.

The study will last 48 weeks during which time participants will make 21 visits to ACRIA. All blood tests, study visits and study drugs will be provided at no charge to the participants. Once enrolled in the study, there will be a reimbursement of $25 per visit to cover lost time from work, transportation costs and/or meals. For more information, call Dr. Douglas Mendez at 212-924-3934, ext. 126.


Ampligen and Treatment Interruptions: Protocol AMP 720

This trial will study whether Ampligen can extend the time people can interrupt HAART, before viral load rebounds.

Adults who are taking HAART, and who have a CD4 count over 400 and viral load below 50, will take HAART and receive infusions of Ampligen, or take HAART without Ampligen, for 2 months. Then, HAART will be stopped and viral load will be checked weekly. If viral load rises above 5,000, HAART will be restarted. If viral load drops below 50 for 2 months, HAART will be stopped again. This pattern will continue for the rest of the study. People who don't receive Ampligen can take it after 14 months.

The study will last approximately 128 weeks during which time participants will make 128 visits to ACRIA. All blood tests, study visits and study drug will be provided at no charge to the participants. Once enrolled in the study, there will be a reimbursement of $25 per visit to cover lost time from work, transportation costs and/or meals. For more information, call Dr. Douglas Mendez at 212-924-3934 ext 126.





  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by AIDS Community Research Initiative of America. It is a part of the publication ACRIA Update. Visit ACRIA's website to find out more about their activities, publications and services.
 

Tools
 

Advertisement